-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-509588-25-00
4
2025-02-11
Hepatitis B
-
2024-514228-18-00
4
2025-01-16
Asthma in adults who remain uncontrolled despite medium to high dose I
-
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)
-
2024-511882-13-01
5
2024-11-19
Cardiac failure
-
2023-504040-34-01
5
2024-11-12
Crohn’s Disease
-
2024-516965-35-00
5
2024-10-28
Immune system disorders
-
2023-507891-31-00
10
2024-10-11
Human Immunodeficiency Virus (HIV-1) infection
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2023-504922-20-00
5
2024-08-23
Hypercholesterolemia
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2022-502781-24-01
5
2024-06-05
ASCVD - Atherosclerotic Cardiovascular Disease
-
2023-506457-38-00
5
2024-06-05
Chronic kidney disease (CKD) and hypertension.
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-507685-10-00
5
2024-05-30
High-Risk Non-muscle-invasive Bladder Cancer
-
2023-506669-70-00
5
2024-04-30
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
-
2022-502099-22-01
5
2024-04-29
HIV-1 Infection
-
2023-503231-17-00
5
2024-04-26
Unresectable Pleural Mesothelioma
-
2023-506735-15-00
5
2024-04-05
Erythropoietic Protoporphyria or X-Linked Protoporphyria
-
2023-504471-25-00
5
2024-03-01
Fibrotic Lung Disease
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2023-506017-22-00
4
2024-02-16
Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer
-
2023-504993-40-00
5
2024-02-14
Human immunodeficiency virus (HIV)
-
2022-502102-32-00
5
2023-11-16
Primary Immunoglobulin A (IgA) Nephropathy